Pneumococcal Vaccine
Excerpt
A new vaccine for the prevention of bacteremic and nonbacteremic infection from Streptococcus pneumoniae has been licensed and is available. Like the previous pneumococcal vaccine, the new vaccine is composed of purified capsular pneumococcal antigens. The new vaccine is different from the previously available vaccine in two respects: it contains antigens to 23 serotypes of pneumococcus rather than the 14 serotypes in the previous formulation; and the dose of each antigen in the vaccine has been reduced from 50 µg to 25 µg. The 23 serotypes in the new vaccine account for approximately 85% of bacteremic pneumococcal disease in the
This 100-word excerpt has been provided in the absence of an abstract.
Acknowledgments
ACKNOWLEDGMENTS: The Clinical Efficacy Assessment Project (CEAP) of the American College of Physicians is designed to evaluate and inform College members and others about the safety and efficacy of diagnostic and therapeutic modalities. Evaluation of technologies begins with a notice in Annals of Internal Medicine and the ACP Observer inviting comments. Appropriate members of the Council of Medical Societies and the Council of Subspecialty Societies as well as other experts are asked to review technologies. The CEAP statements thus represent a synthesis of the literature and expert opinion and are intended to reflect the current state-of-the-art knowledge concerning a technology. Statements may be reconsidered as new information becomes available.
Article and Author Information
-
↵* This paper was authored by J. Sanford Schwartz, M.D., and was developed for the Health and Public Policy Committee by the Clinical Efficacy Assessment Subcommittee: Donald E. Olson, M.D., Chairman; David Banta, M.D.; Howard S. Frazier, M.D.; Richard B. Hornick, M.D.; Willis C. Maddrey, M.D.; and Seymour Perry, M.D. Members of the Health and Public Policy Committee for the 1985-86 term include Edwin P. Maynard III, M.D., Chairman; John H. Eisenberg, M.D.; Richard G. Farmer, M.D.; Boy Frame, M.D.; John R. Hogness, M.D.; William L. Hughes, M.D.; Charles E. Lewis, M.D.; Malcolm L. Peterson, M.D.; Richard J. Reitemeier, M.D.; Helen L. Smits, M.D.; and Paul D. Stolley, M.D. This paper was adopted by the Board of Regents on 31 May 1985. This statement supercedes the previous recommendation on pneumococcal vaccine (Ann Intern Med. 1982;96:206-7).
-
Grant support: The development of this paper by the Clinical Efficacy Assessment Project was funded by the John A. Hartford Foundation.
-
▸Requests for reprints should be addressed to Linda Johnson White; Clinical Efficacy Assessment Project, Department of Health and Public Policy, American College of Physicians, 4200 Pine Street; Philadelphia, PA 19104.
- © 1986 American College of Physicians
Most Read
